Literature DB >> 33796512

Intratumoral Heterogeneity in Uveal Melanoma.

Cristina Fonseca1,2, Rita Pinto-Proença2, Sabrina Bergeron2, Luís Miguel Pires3, Júlia Fernandes1, Isabel Marques Carreira3,4,5, Miguel N Burnier2, Rui Proença1.   

Abstract

Tumor biopsies in uveal melanoma (UM) serve mainly the purpose of prognostication and assessment of individual metastatic risk, but can be used for diagnosis in selected cases. The importance of precise information is paramount for selecting adequate surveillance protocols, patient counseling, and optimization of treatment strategies. However, intratumoral heterogeneity and sample representativity are major concerns and can interfere with the correct prediction of the patient's prognosis. We report a series of cases of UM with distinct morphologically identifiable areas, highlighting the differences in clinical behavior, as well as histopathological and genetic features.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Biopsy; Prognosis; Tumor heterogeneity; Uveal melanoma

Year:  2020        PMID: 33796512      PMCID: PMC7989676          DOI: 10.1159/000508517

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  10 in total

1.  Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification.

Authors:  Justyna Dopierala; Bertil E Damato; Sarah L Lake; Azzam F G Taktak; Sarah E Coupland
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-19       Impact factor: 4.799

2.  Transvitreal Retinochoroidal Biopsy Provides a Representative Sample From Choroidal Melanoma for Detection of Chromosome 3 Aberrations.

Authors:  Mette Bagger; Morten T Andersen; Steffen Heegaard; Mette K Andersen; Jens F Kiilgaard
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-09       Impact factor: 4.799

3.  Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Devron H Char; James J Augsburger; Zelia M Correa; Eric Nudleman; Thomas M Aaberg; Michael M Altaweel; David S Bardenstein; Paul T Finger; Brenda L Gallie; George J Harocopos; Peter G Hovland; Hugh D McGowan; Tatyana Milman; Prithvi Mruthyunjaya; E Rand Simpson; Morton E Smith; David J Wilson; William J Wirostko; J William Harbour
Journal:  Ophthalmology       Date:  2012-04-21       Impact factor: 12.079

4.  The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28.

Authors: 
Journal:  Arch Ophthalmol       Date:  2006-12

Review 5.  Uveal melanoma: relatively rare but deadly cancer.

Authors:  S Kaliki; C L Shields
Journal:  Eye (Lond)       Date:  2016-12-02       Impact factor: 3.775

6.  Chromosome 3 intratumor heterogeneity in uveal melanoma.

Authors:  Hanneke W Mensink; Jolanda Vaarwater; Emine Kiliç; Nicole C Naus; Neeltje Mooy; Gre Luyten; Hennie T Brüggenwirth; Dion Paridaens; Annelies de Klein
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-09-29       Impact factor: 4.799

7.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

8.  Acquired homozygosity (isodisomy) of chromosome 3 during clonal evolution of a uveal melanoma: association with morphologic heterogeneity.

Authors:  V A White; B K McNeil; L Thiberville; D E Horsman
Journal:  Genes Chromosomes Cancer       Date:  1996-02       Impact factor: 5.006

Review 9.  Uveal melanoma: estimating prognosis.

Authors:  Swathi Kaliki; Carol L Shields; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

10.  Case report: an atypical peripapillary uveal melanoma.

Authors:  Li-Anne Lim; Cristina Miyamoto; Paula Blanco; Silvin Bakalian; Miguel N Burnier
Journal:  BMC Ophthalmol       Date:  2014-02-03       Impact factor: 2.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.